Jump To Section
Featured Stories
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
US FDA Opens Door For J&J's Spravato To Another MDD Population
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
CymaBay’s Stalled Seladelpar Back In Play For PBC
Weeks after lifting of an FDA clinical hold, CymaBay says it will resume development of its PPAR agonist in primary biliary cholangitis. It will initiate a new Phase III trial but also use data from a terminated Phase III study.
Coronavirus Spotlight
US Studies Hold The Key To COVID-19 Vaccines Race
US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
COVID-19 Pipeline Tracker
Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.
Infographics
The 2020 Worldwide Pharma & Biotech Industry R&D Scene
INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2020.
COVID-19: The Race To Develop A Vaccine
The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.
Titans Of Pharma 2020: A Bumper Year For Top Executive Compensation
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Top-Level Churn At Cipla's India Business
A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.
Recordati Raises Forecast for Isturisa After Smooth Launches
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Sun Loses Shine In Q1, Testing Times In US
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
Novo Nordisk Q2 Preview: Focus On Rybelsus, Ozempic And Payors
Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity
The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses.
Novartis's Piqray Gets Europe Green Light At Last
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pipeline Watch: Phase III Starts With AL001, Beremagene Geperpavec And Relacorilant
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Coronavirus Update: Russia Plans First Vaccinations In October
Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.